"Wells Fargo lowered its price target on Boston Scientific stock to $75 from $94, acknowledging management's right-sizing after weakness in WATCHMAN, U.S. electrophysiology, and Urology. Barclays argued that with expectations reset, attractive end markets, and buybacks coming, BSX will 'significantly outperform' over the next year."
"Needham kept its Buy rating on BSX stock while acknowledging near-term choppiness. The common thread: the fundamental franchise is intact, and the guidance cut de-risks the narrative."
"Boston Scientific is a global medical device maker with leading franchises in cardiovascular, endoscopy, urology, and neuromodulation. Q1 revenue came in at $5.203 billion, up 11.6% year over year, with organic growth of 9.4% and adjusted EPS of 80 cents, extending a four-quarter beat streak."
Boston Scientific stock has declined significantly in 2026 following a reduction in full-year guidance. Major firms like Wells Fargo, Barclays, and Needham have adjusted their price targets while retaining bullish ratings. The revised forecasts reflect a more realistic outlook after management's adjustments due to weaknesses in specific segments. Despite near-term volatility, analysts believe the company's fundamental growth story remains intact, with expectations reset for future performance. The company reported strong revenue growth in Q1, indicating resilience in its core franchises.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]